A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Trial Profile

A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Alisertib (Primary) ; Gemcitabine; Pralatrexate; Romidepsin
  • Indications Peripheral T-cell lymphoma; T cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms LUMIERE
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 30 Mar 2017 Planned End Date changed from 1 Feb 2017 to 31 Dec 2017.
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 05 Nov 2015 Results from this trial will be presented at the 57th American Society of Hematology (ASH) Annual Meeting, according to a Takeda Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top